CTAD 2025
We will be present at this event with meeting spaces available.
Poster Sessions:
Wednesday, December 3, 7:15am - 5:30pm: Group 7: "CLINICAL TRIALS: BIOMARKERS INCLUDING PLASMA"
- P236 ADxPLORER: filling the gap for early-stage fluid biomarker research on the fully automated LUMIPULSE® G1200 Platform
- Presenter: Nathan Blancke, ADx NeuroSciences
- P234 Performance testing of the novel DDC Xplorer Lumipulse G1200 immunoassay for measuring DOPA Decarboxylase in Cerebrospinal Fluid (CSF)
- Presenter: Erik Stoops, ADx NeuroSciences
Flash Presentation:
Wednesday, December 3, 3:50pm - 4:20pm: Session 4 - Multiomics and Precision Diagnostics
- Fujirebio/ADx NeuroSciences — ADxPLORER qualified assays for early biomarker access "The chicken or the egg - why is ADxPLORER filling a crucial gap?"
Late Breaking Communications (LUMIPULSE):
Thursday, December 4, 8:45am
- LB24 pTau 217 performance to separate Alzheimer's disease biological stage is not increased by adding demographic or clinical information
- Contributor Mention: Manu Vandijck, Fujirebio Europe N.V. - Gent (Belgium)